Acute Graft Versus Host Disease - 162 Studies Found
| Active, not recruiting |
: Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation : Graft vs Host Disease : 2012-08-13 : Drug: Atorvastatin calcium 40 mg PO daily Other Name |
| Completed |
: A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension- :
|
| Recruiting |
: Ruxolitinib In GvHD : Graft vs Host Disease : 2015-03-10 :
|
| Recruiting |
: Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections :
|
| Recruiting |
: Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease :
: 1999-11-03 |
| Completed |
: Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease :
|
| Completed |
: Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute GVHD. : Graft vs Host Disease : 2005-08-25 :
|
| Recruiting |
: A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD : Grades B-D aGVHD : 2014-12-30 : Drug: remestemcel-L Subjects will be treated with intravenous (IV) remestemcel-L at a dose of 2 x 10e6 M |
| Completed |
: Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease : Graft-versus-Host Disease : 2006-12-06 : Drug: Bortezomib Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest |
| Recruiting |
: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant :
|